Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19-CAR-Lenti_ALLO |
Synonyms | |
Therapy Description |
CD19-CAR-Lenti_ALLO comprises allogeneic T-cells engineered with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting CD19 and containing the TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (PMID: 37172203). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19-CAR-Lenti_ALLO | CD19-CAR_Lenti_ALLO | CD19 Immune Cell Therapy 62 | CD19-CAR-Lenti_ALLO comprises allogeneic T-cells engineered with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting CD19 and containing the TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (PMID: 37172203). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06080191 | Phase I | CD19-CAR-Lenti_ALLO | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | Recruiting | ITA | 0 |